Edition:
United Kingdom

People: Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

2.50USD
19 Jul 2019
Change (% chg)

$-0.04 (-1.57%)
Prev Close
$2.54
Open
$2.56
Day's High
$2.66
Day's Low
$2.48
Volume
15,235
Avg. Vol
32,604
52-wk High
$5.56
52-wk Low
$1.30

Sachse, Richard 

Dr. Richard Sachse, M.D. Ph.D. is Senior Vice President, Chief Scientific Officer, Chief Medical Officer of Aeterna Zentaris Inc. He holds a degree in medicine from the Friedrich-Alexander-University Erlangen, in Germany, and a board certification in Clinical Pharmacology. With more than 20 years experience as a physician and scientist, he has extensive expertise in a variety of different therapeutic areas, including endocrinology and oncology. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic, as well as in the design and implementation of clinical pharmacology programs, including all required profiling studies and activities, enabling successful registration of products at the international level. From 1996 to 2000, he was International Project Leader at the Bayer AG Institute for Clinical Pharmacology, and Principal Investigator at the Bayer Clinical Pharmacology Unit, implementing innovative exploratory development tools, including biomarkers to demonstrate early Proof of Concept. From 2001 to 2006, Dr. Sachse held a variety of different management positions within early and late phase clinical development programs, including responsibilities for completed Phase 3 programs leading to successful NDA/MAA submissions. In 2007, after a merger, he became Senior Director, Head of Experimental Medicine, at UCB in Belgium, where he managed the implementation of novel biomarkers in clinical development to provide data supporting identification of appropriate target indication and target population. In 2010, Dr. Sachse became Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.

Basic Compensation

Total Annual Compensation, USD 277,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 294,067
Fiscal Year Total, USD 571,567

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --